Your browser is no longer supported. Please, upgrade your browser.
Settings
LGND Ligand Pharmaceuticals Incorporated daily Stock Chart
LGND [NASD]
Ligand Pharmaceuticals Incorporated
Index- P/E- EPS (ttm)-3.44 Insider Own2.80% Shs Outstand16.53M Perf Week4.28%
Market Cap1.64B Forward P/E24.98 EPS next Y4.19 Insider Trans-3.19% Shs Float15.27M Perf Month8.72%
Income-61.20M PEG- EPS next Q0.76 Inst Own- Short Float60.13% Perf Quarter2.10%
Sales110.00M P/S14.92 EPS this Y432.60% Inst Trans0.95% Short Ratio16.54 Perf Half Y-4.63%
Book/sh40.04 P/B2.62 EPS next Y13.54% ROA-4.10% Target Price176.33 Perf Year-6.94%
Cash/sh49.28 P/C2.13 EPS next 5Y18.63% ROE-7.40% 52W Range57.24 - 122.08 Perf YTD0.46%
Dividend- P/FCF- EPS past 5Y124.30% ROI45.50% 52W High-14.18% Beta1.60
Dividend %- Quick Ratio40.30 Sales past 5Y13.30% Gross Margin88.90% 52W Low83.04% ATR6.28
Employees115 Current Ratio40.60 Sales Q/Q-23.70% Oper. Margin-14.20% RSI (14)59.32 Volatility5.14% 5.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-104.70% Profit Margin-55.60% Rel Volume0.51 Prev Close105.87
ShortableYes LT Debt/Eq0.67 EarningsMay 06 AMC Payout- Avg Volume555.15K Price104.77
Recom2.20 SMA203.84% SMA5017.56% SMA2007.48% Volume291,256 Change-1.04%
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Oct-29-18Upgrade ROTH Capital Neutral → Buy
Oct-02-18Reiterated H.C. Wainwright Buy $270 → $280
Sep-11-18Reiterated Argus Buy $260 → $300
Aug-17-18Initiated Goldman Neutral $256
Aug-08-18Downgrade ROTH Capital Buy → Neutral
Jun-21-18Initiated Argus Buy $260
Dec-27-17Reiterated H.C. Wainwright Buy $163 → $169
Sep-05-17Resumed H.C. Wainwright Buy $150
Oct-05-16Reiterated H.C. Wainwright Buy $146 → $160
Aug-05-16Downgrade Deutsche Bank Hold → Sell $104 → $110
Mar-11-16Initiated Sidoti Buy
Mar-03-16Initiated H.C. Wainwright Buy $146
Dec-18-15Reiterated ROTH Capital Buy $144 → $146
May-25-20 04:27PM  Edited Transcript of LGND earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-22-20 08:58AM  Update: Ligand Pharmaceuticals (NASDAQ:LGND) Stock Gained 20% In The Last Five Years Simply Wall St.
May-14-20 11:50AM  Should Value Investors Buy Ligand Pharmaceuticals (LGND) Stock? Zacks
May-07-20 04:00PM  Ligand Pharmaceuticals Inc (LGND) Q1 2020 Earnings Call Transcript Motley Fool
11:40AM  LGND vs. TECH: Which Stock Should Value Investors Buy Now? Zacks
11:11AM  Ligand (LGND) Beats on Q1 Earnings & Sales, Raises View Zacks
May-06-20 05:45PM  Ligand Pharmaceuticals (LGND) Q1 Earnings and Revenues Beat Estimates Zacks
04:01PM  Ligand Reports First Quarter 2020 Financial Results Business Wire
May-03-20 03:37PM  A Potentially Undervalued Trio to Consider GuruFocus.com
Apr-29-20 12:34PM  Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for Zacks +8.52%
Apr-22-20 08:30AM  Ligands First Quarter Financial Results to be Reported May 6th Business Wire
Apr-17-20 08:00AM  ImmunoPrecise Provides Updates on B Cell Select and Deep Display Programs for SARS-CoV-2 Antibody Discovery CNW Group +6.07%
Apr-09-20 10:51AM  Is the Options Market Predicting a Spike in Ligand (LGND) Stock? Zacks
Apr-08-20 12:10PM  Hedge Funds Are Betting On Ligand Pharmaceuticals Inc. (LGND) Insider Monkey +6.11%
Apr-07-20 12:16PM  Should You Take Comfort From Insider Transactions At Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)? Simply Wall St.
Apr-06-20 07:00AM  Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call Business Wire +5.75%
Apr-02-20 04:02PM  Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies Business Wire +5.37%
Mar-18-20 02:29PM  Top Biotech Stocks for Q2 2020 Investopedia
Mar-10-20 08:00AM  Ligands Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com Business Wire
Mar-09-20 01:30PM  6 Cheap Health Care Stocks GuruFocus.com -12.03%
Mar-07-20 11:30AM  Ligand (LGND) Up 16.3% Since Last Earnings Report: Can It Continue? Zacks
Mar-02-20 08:00AM  Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March Business Wire +9.82%
Feb-27-20 08:00AM  Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales Business Wire
Feb-19-20 08:00PM  INVESTOR ALERT: BDX LGND LOPE SBT: Kirby McInerney LLP Continues Investigation of Shareholder Claims GlobeNewswire
06:30AM  Hedge Fund Alleges SEC Bias in Short-Selling Case Barrons.com
Feb-17-20 11:12AM  Edited Transcript of LGND earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-11-20 04:14PM  Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen Business Wire
Feb-07-20 10:49AM  Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up Zacks
Feb-06-20 06:35PM  Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates Zacks
04:01PM  Ligand Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-03-20 08:30AM  Ligand's Technologies Support and Enable Potential Coronavirus Treatments Business Wire
Jan-13-20 04:02PM  Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics Business Wire
Jan-09-20 02:47PM  Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th Business Wire
Jan-08-20 11:04AM  Does Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Have A High Beta? Simply Wall St.
Jan-06-20 11:40AM  LGND vs. ALKS: Which Stock Is the Better Value Option? Zacks
Dec-23-19 08:30AM  Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine Business Wire
Dec-20-19 05:03PM  Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy ? Insider Monkey
Dec-12-19 10:41PM  Top stock picks for 2020: Making money with midsize firms MarketWatch
Dec-06-19 08:00AM  12 Biotech Stocks Primed For A Short Squeeze Benzinga
Dec-05-19 11:31AM  Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report? Zacks
Dec-02-19 08:30AM  Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi Business Wire
Nov-19-19 07:16AM  Edited Transcript of LGND earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 08:30AM  Ligand Pharmaceuticals Ranked in Deloittes 2019 Technology Fast 500 Business Wire
Nov-08-19 08:30AM  Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol Business Wire +7.06%
Nov-07-19 08:30AM  Ligand to Participate in the Stephens 2019 Nashville Investment Conference Business Wire
Nov-06-19 09:33AM  Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down Zacks -8.57%
Nov-05-19 06:15PM  Ligand Pharmaceuticals (LGND) Q3 Earnings Miss Estimates Zacks
04:02PM  Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals CNW Group
04:01PM  Ligand Reports Third Quarter 2019 Financial Results Business Wire
Oct-29-19 10:32AM  Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-25-19 10:13AM  Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ? Insider Monkey
Oct-22-19 04:01PM  Ligand to Report Third Quarter 2019 Results on November 5th Business Wire
Oct-15-19 09:00AM  Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors Business Wire
Oct-10-19 10:08AM  Who Has Been Buying Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares? Simply Wall St.
Oct-03-19 08:00AM  ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom CNW Group +5.03%
Sep-23-19 10:01AM  Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer GlobeNewswire
Sep-13-19 08:42AM  Ligand (LGND) Surges: Stock Moves 6.3% Higher Zacks
Sep-12-19 06:41AM  Ligand Pharmaceuticals approves new $500 million stock buyback program MarketWatch +6.26%
Aug-29-19 09:31AM  Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report? Zacks
09:00AM  Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference Business Wire
Aug-23-19 07:38AM  Retrophin Down on Neurological Disorder Drug Study Failure Zacks
Aug-14-19 06:15PM  3 Top Biotech Stocks to Buy in August Motley Fool
Aug-12-19 09:00AM  Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China Business Wire
Aug-03-19 08:51AM  Edited Transcript of LGND earnings conference call or presentation 30-Jul-19 1:00pm GMT Thomson Reuters StreetEvents
Jul-31-19 09:15PM  Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $176,582 of Shares GuruFocus.com
10:44AM  Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat Zacks
Jul-30-19 06:09PM  Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Call Transcript Motley Fool -11.38%
01:32PM  Long-Time Ligand Short Increases Position As Shares Fall 11% On Earnings Benzinga
09:25AM  Ligand Pharmaceuticals (LGND) Surpasses Q2 Earnings and Revenue Estimates Zacks
08:00AM  Ligand Reports Second Quarter 2019 Financial Results Business Wire
Jul-23-19 04:15PM  Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company Business Wire
10:32AM  Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-17-19 01:49PM  Andrew Left's Citron Capital posted net return of 24.7% in 1st half of 2019 Reuters
Jul-16-19 11:19AM  Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP PR Newswire
Jul-15-19 09:00AM  Ligand to Report Second Quarter 2019 Results on July 30th Business Wire
Jul-12-19 07:36AM  Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expensive For A Reason? A Look At Its Intrinsic Value Simply Wall St.
Jul-10-19 09:00AM  Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol Business Wire
Jul-08-19 08:30AM  Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation PR Newswire
Jul-01-19 09:00AM  ZULRESSO (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligands Captisol® in its Formulation, Launched by Sage Therapeutics Business Wire
Jun-20-19 02:52PM  What does Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Balance Sheet Tell Us About Its Future? Simply Wall St.
Jun-13-19 09:36AM  Ligand Inks Oncology Drug Discovery Deal With PhoreMost Zacks
Jun-12-19 09:00AM  Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target Business Wire
Jun-10-19 01:54PM  Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy? Insider Monkey
Jun-03-19 11:52AM  Should You Worry About Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Salary Level? Simply Wall St.
May-31-19 09:15PM  Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $108,200 of Shares GuruFocus.com
May-20-19 09:04AM  Ligand Grants Preclinical Candidate Rights to UK-based Firm Zacks
May-17-19 09:00AM  Ligand Licenses VER250840 to Cumulus Oncology Business Wire
May-14-19 10:15PM  Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $283,750 of Shares GuruFocus.com
May-10-19 12:21PM  A Closer Look At Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive ROE Simply Wall St.
May-09-19 06:57AM  AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates Zacks
May-08-19 04:00PM  Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View Zacks
May-07-19 09:42PM  Edited Transcript of LGND earnings conference call or presentation 2-May-19 8:30pm GMT Thomson Reuters StreetEvents
01:51PM  Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss Zacks
08:56AM  Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1 Zacks
May-06-19 02:52PM  Novan adds more cash, now confident it can execute American City Business Journals
09:00AM  Novan Completes Funding Transaction with Ligand Pharmaceuticals GlobeNewswire
09:00AM  Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc. Business Wire
May-03-19 08:42AM  Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down Zacks
07:49AM  The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen Benzinga
May-02-19 09:56PM  Ligand Pharmaceuticals Incorporated (LGND) Q1 2019 Earnings Call Transcript Motley Fool
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WPresident and COOMar 13Option Exercise21.922,00043,840157,449Mar 13 06:33 PM
FOEHR MATTHEW WPresident and COOFeb 27Option Exercise15.898,931141,941160,968Feb 27 08:35 PM
FOEHR MATTHEW WPresident and COOFeb 27Sale110.007,225794,750153,743Feb 27 08:35 PM
FOEHR MATTHEW WPresident and COOFeb 14Option Exercise14.477,225104,546163,454Feb 18 05:09 PM
FOEHR MATTHEW WPresident and COOFeb 14Sale95.847,225692,467156,229Feb 18 05:09 PM
HIGGINS JOHN LChief Executive OfficerFeb 13Option Exercise9.9648,125479,325201,739Feb 18 05:11 PM
FOEHR MATTHEW WPresident and COOFeb 13Option Exercise21.9249610,872148,833Feb 18 05:09 PM
FOEHR MATTHEW WPresident and COONov 12Option Exercise21.921,00121,942144,620Nov 13 04:07 PM
FOEHR MATTHEW WPresident and COOSep 05Option Exercise21.921,00522,030143,619Sep 05 07:24 PM
Aryeh JasonDirectorSep 03Buy87.0175065,25867,203Sep 04 07:30 PM
Korenberg Matthew EEVP,Finance & Strategy and CFOSep 03Buy86.1850043,09117,151Sep 03 07:34 PM
FOEHR MATTHEW WPresident and COOAug 12Option Exercise21.921,16325,493142,614Aug 13 01:45 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryAug 05Option Exercise67.721,09374,01347,172Aug 06 05:17 PM
Aryeh JasonDirectorAug 05Buy90.0174667,14666,453Aug 06 05:18 PM
Patel SunilDirectorAug 02Buy95.981,00095,98026,359Aug 05 06:56 PM
Davis Todd CDirectorAug 02Buy93.591,00093,59449,474Aug 05 07:04 PM
LAMATTINA JOHN LDirectorAug 01Option Exercise32.302,50080,75024,784Aug 05 07:00 PM
HIGGINS JOHN LChief Executive OfficerJul 31Buy95.451,850176,583146,749Jul 31 07:26 PM
Aryeh JasonDirectorJul 31Buy93.0075470,12265,707Jul 31 06:50 PM
Sabba Stephen LDirectorJul 31Sale94.454,091386,39523,600Aug 01 02:49 PM
Aryeh JasonDirectorJul 30Buy100.223,000300,66364,953Jul 31 06:50 PM
Aryeh JasonDirectorJul 29Buy106.0125026,50361,953Jul 31 06:50 PM
FOEHR MATTHEW WPresident and COOJun 11Option Exercise21.921,00422,008141,451Jun 12 06:50 PM
Aryeh JasonDirectorJun 11Buy107.0125026,75361,703Jun 12 06:51 PM
HIGGINS JOHN LChief Executive OfficerMay 31Buy108.201,000108,202144,899May 31 07:29 PM
Aryeh JasonDirectorMay 31Buy108.5150054,25560,618May 31 06:27 PM
Aryeh JasonDirectorMay 30Buy110.0125027,50360,118May 31 06:27 PM
Aryeh JasonDirectorMay 29Buy111.0125027,75359,868May 31 06:27 PM